A study testing whether a study medicine from Novo Nordisk, cagrisema, can lower blood sugar and help with weight.

Who can join

Adults 18 to 64, have type 2 diabetes, BMI 25+.

What you take

cagrisema, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.

How long it lasts

The study runs about 14 months.

What you get

The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.

What this study is for

Full study title: A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes.

Primary condition: Diabetes Mellitus, Type 2.

Who can join, in detail

Key inclusion criteria

• Male or female (sex assigned at birth, inclusive of all gender identities).
• Age 18-64 years (both inclusive) at the time of signing the informed consent.
• Diagnosed with type 2 diabetes mellitus greater than or equal to (>=) 180 days before screening.
• Glycated haemoglobin (HbA1c) 7.0-10.5 percent (%) (53-91 [millimoles per mole] mmol/mol) (both inclusive) as determined by the central laboratory at screening.
• Stable daily dose >= 90 days before screening of metformin at effective or maximum tolerated dose as judged by the investigator.

Key exclusion criteria

• Renal impairment with estimated Glomerular Filtration Rate (eGFR) < 30 millilitre per minute per 1.73 square metre (mL/min/1.73 m^2) as determined by the central laboratory at screening.
• Treatment with any anti-diabetic or anti-obesity medication (irrespective of indication) other than stated in the inclusion criteria within 90 days before screening.
• Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation.
• Previous exposure to CagriSema in a clinical study.

Where this study is enrolling

This trial has 21 US sites across 10 states. Contact the site coordinator directly to start the screening process.

Timeline

Started enrolling: 2026-08-27. Expected completion: 2027-10-13. Last updated on ClinicalTrials.gov: 2026-03-30.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Other GLP-1 clinical trials

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact